Sex differences in nevirapine rash

Clinical Infectious Diseases

Volumn 32, Issue 1, 2001, Pages 124-129

  Bersoff Matcha, Susan J ^a   Miller, William C ^b   Aberg, Judith A ^c   Van der Horst, Charles ^b   Hamrick, H James ^b   Powderly, William G ^a   Mundy, Linda M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HIV INFECTIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEVIRAPINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEX CHARACTERISTICS;

EID: 0035134608     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317536     Document Type: Article

References (30)

1. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus
2. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection
3. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients
4. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients
5. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
6. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans
7. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection
8. Nevirapine: A review of its development, pharmacological profile and potential for clinical use
9. Clinical experience with non-nucleoside reverse transcriptase inhibitors
10. Blood-brain barrier properties of human immunodeficiency virus antiretrovirals
11. Current clinical experience with nevirapine for HIV infection
12. Safety of high dose nevirapine (NVP) after 200 mg/d lead-in [abstract PO-B26-2109]. 9th International Conference on AIDS (Amsterdam, 6-11 June 1993)
13. Binomial regression in GLIM: Estimating risk ratios and risk differences
14. Cutaneous eruptions associated with nevirapine (NVP) therapy in HIV-1 infected individuals [abstract Mo.B. 1202]. 11th International Conference on AIDS (Vancouver, BC, 7-12 July 1996)
15. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity
16. 3: AIDS Clinical Trials Group protocol 208
17. Nevirapine-associated Steven's-Johnson syndrome
18. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash [abstract I-64a]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, (San Diego, 24-27 September 1998)
19. Gender difference in adverse drug reactions
20. Rates of cutaneous reactions to drugs: A report from the Boston Collaborative Drug Surveillance Program
21. Drug induced cutaneous reactions: A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982
22. Cutaneous drug reactions: Clinical types and causative agents
23. Dermatologic adverse drug reactions in a family medicine setting
24. Drug eruptions: A series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-70
25. Adverse reactions to co-trimoxazole in hospitalized medical patients
26. Prospective study of ampicillin rash
27. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis
28. Coumarin-induced skin necrosis: Incidence, mechanisms, management and avoidance
29. Update: Trends in AIDS incidence - United States, 1996